Document Detail


Signalling pathways that mediate skeletal muscle hypertrophy and atrophy.
MedLine Citation:
PMID:  12563267     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Atrophy of skeletal muscle is a serious consequence of numerous diseases, including cancer and AIDS. Successful treatments for skeletal muscle atrophy could either block protein degradation pathways activated during atrophy or stimulate protein synthesis pathways induced during skeletal muscle hypertrophy. This perspective will focus on the signalling pathways that control skeletal muscle atrophy and hypertrophy, including the recently identified ubiquitin ligases muscle RING finger 1 (MuRF1) and muscle atrophy F-box (MAFbx), as a basis to develop targets for pharmacologic intervention in muscle disease.
Authors:
David J Glass
Related Documents :
3098997 - Effects of resistive exercise on skeletal muscle in marrow transplant recipients receiv...
9815007 - Testosterone injection stimulates net protein synthesis but not tissue amino acid trans...
6809327 - Metabolism in peripheral tissues in cancer patients.
23713027 - Effects of the insertional and appositional forces of the canine diaphragm on the lower...
19062307 - The activity pattern of shoulder muscles in subjects with and without subacromial impin...
7820977 - Growth hormone (gh) treatment in gh-deficient adults: effects on muscle size, strength ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Nature cell biology     Volume:  5     ISSN:  1465-7392     ISO Abbreviation:  Nat. Cell Biol.     Publication Date:  2003 Feb 
Date Detail:
Created Date:  2003-02-03     Completed Date:  2003-03-27     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  100890575     Medline TA:  Nat Cell Biol     Country:  England    
Other Details:
Languages:  eng     Pagination:  87-90     Citation Subset:  IM    
Affiliation:
Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, USA. david.glass@regeneron.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
1-Phosphatidylinositol 3-Kinase / metabolism
Animals
Calcineurin / metabolism
Humans
Hypertrophy / metabolism
Insulin-Like Growth Factor I / metabolism
Ligases / metabolism
Muscle Proteins / metabolism
Muscle, Skeletal / metabolism*,  pathology*
Muscular Atrophy / metabolism*
Protein-Serine-Threonine Kinases*
Proto-Oncogene Proteins / metabolism
Proto-Oncogene Proteins c-akt
Receptors, Adrenergic, beta-2 / metabolism
SKP Cullin F-Box Protein Ligases*
Signal Transduction / physiology*
Ubiquitin-Protein Ligases*
Chemical
Reg. No./Substance:
0/Muscle Proteins; 0/Proto-Oncogene Proteins; 0/Receptors, Adrenergic, beta-2; 67763-96-6/Insulin-Like Growth Factor I; EC 2.7.1.137/1-Phosphatidylinositol 3-Kinase; EC 2.7.11.1/Protein-Serine-Threonine Kinases; EC 2.7.11.1/Proto-Oncogene Proteins c-akt; EC 3.1.3.16/Calcineurin; EC 6.-/Ligases; EC 6.3.2.19/FBXO32 protein, human; EC 6.3.2.19/SKP Cullin F-Box Protein Ligases; EC 6.3.2.19/TRIM63 protein, human; EC 6.3.2.19/Ubiquitin-Protein Ligases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Combinations of muscle synergies in the construction of a natural motor behavior.
Next Document:  Developmental control of cell morphogenesis: a focus on membrane growth.